About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent…
About the LATITUDE Psoriasis Phase 3 Studies
The Latitude Phase 3 psoriasis studies ( NCT06088043 and NCT06108544) are global, multicenter, randomized, double-blind, placebo- and active comparator-c… [+13104 chars]
